AZN vs FORA

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

FORA exhibits severe fundamental weakness as evidenced by a Piotroski F-Score of 2/9, indicating poor operational efficiency and financial health. While the company maintains a debt-free balance sheet and strong liquidity (Current Ratio 2.96), it is struggling to translate 37% revenue growth into bottom-line profitability. The technical trend is completely bearish (0/100) and the 5-year price performance is devastating (-82.8%), suggesting a long-term loss of investor confidence. Despite a healthy gross margin of 53.21%, the negative operating margins and lack of deterministic value markers make this a high-risk speculative play.